Sign in

    Brett Netson

    Managing Director and Senior Equity Research Analyst at Leerink Partners

    Brett Netson is a Managing Director and Senior Equity Research Analyst at Leerink Partners, specializing in biotechnology and pharmaceutical sector equity analysis with deep expertise covering innovative therapeutics companies such as Moderna, BioNTech, and Regeneron Pharmaceuticals. Known for a highly analytical approach, he has developed a reputation for prescient stock recommendations, maintaining a published success rate of approximately 64% and an average return exceeding 12% per recommendation on platforms like TipRanks. Netson began his Wall Street career in the early 2000s at UBS before joining Cowen and then Leerink Partners in 2014, where he has since advanced into leadership roles. Holding FINRA Series 7, 63, and 86/87 licenses, he is recognized for his rigorous financial modeling and has frequently been cited for his top-tier performance in institutional investor surveys.

    Brett Netson's questions to Inspire Medical Systems (INSP) leadership

    Brett Netson's questions to Inspire Medical Systems (INSP) leadership • Q1 2025

    Question

    Brett Netson, on for Mike Kratky from Leerink Partners, asked about the progression of gross margin as the Inspire V mix increases, given the significant inventory build. He also inquired about the performance outside the U.S. (OUS) and any foreign exchange impacts.

    Answer

    CFO Richard Buchholz reiterated the full-year gross margin guidance of 84% to 86% and confirmed that Inspire V is accretive to margins, excluding price changes. He noted that Inspire IV will continue to be manufactured for international markets pending approval. Regarding OUS, he stated there was no real FX impact in Q1 but that the company is seeing some FX headwinds in the second quarter.

    Ask Fintool Equity Research AI